
IPA Valuation
Immunoprecise Antibodies Ltd
- Overview
- Forecast
- Valuation
- Earnings
IPA Relative Valuation
IPA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, IPA is overvalued; if below, it's undervalued.
Historical Valuation
Immunoprecise Antibodies Ltd (IPA) is now in the Fair zone, suggesting that its current forward PS ratio of 5.70 is considered Fairly compared with the five-year average of -2.44. The fair price of Immunoprecise Antibodies Ltd (IPA) is between 1.89 to 4.48 according to relative valuation methord.
Relative Value
Fair Zone
1.89-4.48
Current Price:2.64
Fair
-26.64
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Immunoprecise Antibodies Ltd. (IPA) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -3.53. The thresholds are as follows: Strongly Undervalued below -46.00, Undervalued between -46.00 and -24.76, Fairly Valued between 17.70 and -24.76, Overvalued between 17.70 and 38.94, and Strongly Overvalued above 38.94. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-29.76
EV/EBIT
Immunoprecise Antibodies Ltd. (IPA) has a current EV/EBIT of -29.76. The 5-year average EV/EBIT is -17.24. The thresholds are as follows: Strongly Undervalued below -76.20, Undervalued between -76.20 and -46.72, Fairly Valued between 12.24 and -46.72, Overvalued between 12.24 and 41.72, and Strongly Overvalued above 41.72. The current Forward EV/EBIT of -29.76 falls within the Historic Trend Line -Fairly Valued range.
5.70
PS
Immunoprecise Antibodies Ltd. (IPA) has a current PS of 5.70. The 5-year average PS is 5.12. The thresholds are as follows: Strongly Undervalued below -1.85, Undervalued between -1.85 and 1.63, Fairly Valued between 8.61 and 1.63, Overvalued between 8.61 and 12.10, and Strongly Overvalued above 12.10. The current Forward PS of 5.70 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Immunoprecise Antibodies Ltd. (IPA) has a current P/OCF of 0.00. The 5-year average P/OCF is 13.53. The thresholds are as follows: Strongly Undervalued below -113.91, Undervalued between -113.91 and -50.19, Fairly Valued between 77.25 and -50.19, Overvalued between 77.25 and 140.97, and Strongly Overvalued above 140.97. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Immunoprecise Antibodies Ltd. (IPA) has a current P/FCF of 0.00. The 5-year average P/FCF is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward P/FCF of 0.00 falls within the Strongly Undervalued range.
Immunoprecise Antibodies Ltd (IPA) has a current Price-to-Book (P/B) ratio of 7.56. Compared to its 3-year average P/B ratio of 1.56 , the current P/B ratio is approximately 382.98% higher. Relative to its 5-year average P/B ratio of 2.75, the current P/B ratio is about 174.78% higher. Immunoprecise Antibodies Ltd (IPA) has a Forward Free Cash Flow (FCF) yield of approximately -4.38%. Compared to its 3-year average FCF yield of -20.79%, the current FCF yield is approximately -78.92% lower. Relative to its 5-year average FCF yield of -13.80% , the current FCF yield is about -68.23% lower.
7.83
P/B
Median3y
1.56
Median5y
2.75
-4.38
FCF Yield
Median3y
-20.79
Median5y
-13.80
Competitors Valuation Multiple
The average P/S ratio for IPA's competitors is 11.55, providing a benchmark for relative valuation. Immunoprecise Antibodies Ltd Corp (IPA) exhibits a P/S ratio of 5.70, which is -50.59% above the industry average. Given its robust revenue growth of 8.08%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of IPA increased by 248.34% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -1.03 to -4.43.
The secondary factor is the Revenue Growth, contributed 8.08%to the performance.
Overall, the performance of IPA in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

TRIB
Trinity Biotech PLC
1.560
USD
-10.34%

XTKG
X3 Holdings Co Ltd
2.210
USD
+4.69%

DTSS
Datasea Inc
1.838
USD
-2.75%

LSH
Lakeside Holdings Ltd
0.871
USD
-3.44%

CYN
CYNGN Inc
5.430
USD
+0.74%

AIRI
Air Industries Group
3.040
USD
+0.66%

RMCF
Rocky Mountain Chocolate Factory Inc (Delaware)
1.480
USD
+2.42%

NCRA
Nocera Inc
1.619
USD
+1.19%

CVR
Chicago Rivet & Machine Co
10.740
USD
-1.24%
FAQ

Is Immunoprecise Antibodies Ltd (IPA) currently overvalued or undervalued?
Immunoprecise Antibodies Ltd (IPA) is now in the Fair zone, suggesting that its current forward PS ratio of 5.70 is considered Fairly compared with the five-year average of -2.44. The fair price of Immunoprecise Antibodies Ltd (IPA) is between 1.89 to 4.48 according to relative valuation methord.

What is Immunoprecise Antibodies Ltd (IPA) fair value?

How does IPA's valuation metrics compare to the industry average?

What is the current P/B ratio for Immunoprecise Antibodies Ltd (IPA) as of Aug 22 2025?

What is the current FCF Yield for Immunoprecise Antibodies Ltd (IPA) as of Aug 22 2025?

What is the current Forward P/E ratio for Immunoprecise Antibodies Ltd (IPA) as of Aug 22 2025?
